Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer

The FDA has accepted for review Bristol Myers Squibb & Co Inc's BMY supplemental marketing applications seeking approval for two Opdivo (nivolumab) based combo regimes for esophageal squamous cell carcinoma.
The application cover Opdivo / Yervoy (ipilimumab) and Opdivo / fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for adult patients with unresectable advanced, recurrent or metastatic ESCC.
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 28, 2022.
In CheckMate -648, both Opdivo-based treatment combinations demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy.
Related content: Benzinga's Full FDA Calendar.
Price Action: BMY stock is up 0.75% at $60.68 during the market session on the last check Monday.

Momentum35.26

Growth66.60

QualityNot Available

Value30.88

Short

Medium

Long